deferiprone has been researched along with Adverse Drug Event in 7 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone (L1) has been recommended as an effective oral chelation therapy for patients with beta-thalassemia major (TM)." | 9.12 | Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. ( Hsiao, CC; Jang, RC; Liang, DC; Peng, CT; Wang, LY; Wu, KH; Wu, SF; Yang, CP, 2006) |
| "The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients > or =2 yr with beta-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone." | 5.14 | Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. ( Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A, 2009) |
| "Deferiprone (L1) has been recommended as an effective oral chelation therapy for patients with beta-thalassemia major (TM)." | 5.12 | Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. ( Hsiao, CC; Jang, RC; Liang, DC; Peng, CT; Wang, LY; Wu, KH; Wu, SF; Yang, CP, 2006) |
| "Iron chelating agents - deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) - are used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to siderosis." | 4.93 | Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. ( El Rassi, F; Saliba, AN; Taher, AT, 2016) |
| " Incidence of adverse effects was comparable to that in thalassemic patients." | 2.76 | Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. ( Cermak, J; Hochova, I; Jonasova, A; Neuwirtova, R; Siskova, M; Vondrakova, J; Walterova, L, 2011) |
| "Deferasirox is an oral iron-chelating agent with favorable pharmacokinetics, including a long half-life allowing continuous 24-hour chelation with once-daily dosing." | 2.44 | Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. ( Goldberg, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saliba, AN | 1 |
| El Rassi, F | 1 |
| Taher, AT | 3 |
| Porter, JB | 1 |
| Cappellini, MD | 2 |
| Vichinsky, EP | 1 |
| Taher, A | 1 |
| El-Beshlawy, A | 1 |
| Elalfy, MS | 1 |
| Al Zir, K | 1 |
| Daar, S | 1 |
| Habr, D | 1 |
| Kriemler-Krahn, U | 1 |
| Hmissi, A | 1 |
| Al Jefri, A | 1 |
| Musallam, KM | 1 |
| Cermak, J | 1 |
| Jonasova, A | 1 |
| Vondrakova, J | 1 |
| Walterova, L | 1 |
| Hochova, I | 1 |
| Siskova, M | 1 |
| Neuwirtova, R | 1 |
| Peng, CT | 1 |
| Wu, KH | 1 |
| Wu, SF | 1 |
| Liang, DC | 1 |
| Yang, CP | 1 |
| Jang, RC | 1 |
| Wang, LY | 1 |
| Hsiao, CC | 1 |
| Goldberg, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for deferiprone and Adverse Drug Event
| Article | Year |
|---|---|
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Mana | 2016 |
Overview of iron chelation therapy with desferrioxamine and deferiprone.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Human | 2009 |
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Topics: Benzoates; Deferasirox; Deferiprone; Drug-Related Side Effects and Adverse Reactions; Humans; Iron C | 2007 |
3 trials available for deferiprone and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxa | 2009 |
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Drug Therapy, Combination; Drug-Relate | 2011 |
Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.
Topics: Adolescent; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Therapy, | 2006 |
1 other study available for deferiprone and Adverse Drug Event
| Article | Year |
|---|---|
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Costs; Drug-Related Side | 2008 |